



2025 Companion Spine Divestiture and License Revenue

Purpose and Important Information

Purpose

The purpose of this presentation is to disclose 2025 revenue from the sale of all products sold by Xtant Medical Holdings, Inc. (Company) and its subsidiaries to Companion Spine, LLC and its affiliates (collectively, Companion Spine) effective December 1, 2025 and all 2025 license revenue that is not expected to recur in 2026.

As previously announced, the Company sold its non-core Coflex® and CoFix assets and its international hardware businesses to Companion Spine for a total purchase sale price of \$21.4 million in cash effective December 1, 2025. Since the operating results of these divested businesses will continue to be reflected in the Company's historical consolidated statement of operations prior to December 1, 2025, the Company believes it is helpful to investors to disclose separately quarterly and full year 2025 revenue associated with these divested businesses to facilitate comparisons of the Company's 2026 operational performance to prior year periods.

In addition, as previously announced, the Company recognized \$18.7 million in license revenue in 2025 that likely will not repeat in 2026 due primarily to changes in the reimbursement environment for the Company's SimpliMax™ product effective January 1, 2026 and which changes also will adversely affect a portion of the Company's product revenue in 2026. The loss of this license and product revenue will have an adverse impact on the Company's 2026 revenues and other operating results, including in particular, gross margins. To facilitate comparisons of the Company's 2026 operational performance to prior year periods, the Company believes it is helpful to investors to disclose separately quarterly and full year 2025 license revenue. The Company anticipates that the change in the reimbursement environment also will have an adverse impact on a portion of the Company's future product revenue so the information in this presentation does not present all revenue that is anticipated to be non-recurring in 2026.

Non-GAAP Financial Information

To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this presentation, including Non-Recurring Revenue. Reconciliations of the non-GAAP financial measures used in this presentation to the most comparable GAAP measures for the respective periods can be found in table later in this presentation. The Company's management believes that the presentation of this non-GAAP financial measure provides useful information to investors since non-GAAP financial measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

2025 Companion Spine Divestiture and License Revenue and Reconciliation to Total Revenue

Xtant Medical Holdings, Inc.
Reconciliation of Non-GAAP Non-Recurring Revenue
(In thousands)

| | Three Months Ended | | | | Year Ended |
|---|--------------------|---------------|--------------------|-------------------|-------------------|
| | March 31, 2025 | June 30, 2025 | September 30, 2025 | December 31, 2025 | December 31, 2025 |
| Total Revenue | \$ 32,904 | \$ 35,411 | \$ 33,255 | \$ 32,357 | \$ 133,927 |
| Non-Recurring Revenue | | | | | |
| Revenue associated with Coflex/CoFix assets and Paradigm Spine entities | 5,343 | 5,647 | 5,427 | 3,874 | 20,291 |
| License revenue | 3,620 | 4,975 | 5,483 | 4,645 | 18,723 |
| Total Non-Recurring Revenue | 8,963 | 10,622 | 10,910 | 8,519 | 39,014 |
| Revenue Not Designated as Non-Recurring* | \$ 23,941 | \$ 24,789 | \$ 22,345 | \$ 23,838 | \$ 94,913 |

*Note that the Company anticipates that the change in the reimbursement environment affecting license revenue also will have an adverse impact on a portion of the Company's future product revenue so the information in this presentation does not present all revenue that is anticipated to be non-recurring in 2026.